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The recent diphtheria epidemics in eastern
Europe are a warning that diphtheria can make
a comeback in susceptible populations (1). The
World Health Organization (WHO) recommends
the assessment of diphtheria immunity in
nonepidemic countries, to prevent any indigenous
cases in the European region by the year 2000 (2).
In the Netherlands, the last diphtheria
epidemic occurred during World War II (220,000
cases in 1940 to 1946). Diphtheria vaccination
was introduced in 1952 for persons born after
1945. Under the current schedule, children are
vaccinated at ages 3, 4, 5, and 11 months with
diphtheria, tetanus, pertussis, and inactivated
polio vaccine (DTP-IPV) and at ages 4 and 9
years with DT-IPV. For the past 25 years, the
vaccine coverage for at least three vaccinations
at the age of 12 months has been 97%. Rare
exposure to Corynebacterium diphtheriae may
have led to lack of boosting opportunities (1). As in
other industrialized countries, lack of immunity in
older persons is a reason for concern (3,4).
Furthermore, in the Netherlands, the immune
status of sociogeographically clustered members of
religious communities who refuse vaccination
may be even more unfavorable. Inadequate herd
immunity to diphtheria in these groups could
lead to outbreaks similar to the poliomyelitis
outbreaks in the Netherlands (5). A large
population-based serum bank allowed us to
assess the diphtheria immunity in the general
Dutch population and in persons refusing
vaccination (6).
The Study
From October 1995 through December 1996,
a population-based serum bank with specimens
from 9,948 persons was established (6). Our
objective was to select 40 municipalities with
samples proportional to population size. In each
of five regions, eight municipalities were included.
For each of these 40 municipalities, an age-
stratified sample of 380 persons was drawn from
the population register (7). Participants were
requested to have a blood sample drawn, complete
a questionnaire, and provide immunization and
military service records. Participants were also
selected from eight additional municipalities with
low vaccine coverage to assess the immunity of
members of religious communities that refuse
vaccination. The nationwide sample had 8,357
(55%) participants, and the low vaccine coverage
sample had 1,589 (52.5%). Sufficient serum was
available for testing 7,715 of the nationwide
participants and 1,419 of the participants in the
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In a population-based study in the Netherlands, diphtheria antitoxin antibodies were
measured with a toxin-binding inhibition assay in 9,134 sera from the general population
and religious communities refusing vaccination. The Dutch immunization program
appears to induce long-term protection against diphtheria. However, a substantial
number of adults born before the program was introduced had no protective diphtheria
antibody levels.  Although herd immunity seems adequate, long-term population
protection cannot be assured. As more than 60% of orthodox reformed persons have
antibody levels lower than 0.01 IU/ml, introduction of diphtheria into religious
communities refusing vaccination may constitute a danger of spread of the bacterium.695 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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Methods
Sera were stored at -86°C. The level of
diphtheria antitoxin antibodies was measured
with a toxin-binding inhibition assay (8). In brief,
twofold serum dilution series were incubated
with a fixed amount of toxin, and the
nonneutralized toxin was measured in an enzyme-
linked immunosorbent assay (ELISA) with equine
antitoxin purified from hyperimmune serum as
coat and peroxidase-labeled horse antidiphtheria
IgG as conjugate. International units were
calculated according to the WHO reference
standard serum (10 IU/ml) by the four-parameter
fit method in Kineticalc (KC4, Biolyse) with a
Bio-Tek plate reader (EL312d). The minimum
level of detection was 0.01 IU/ml, and samples
below this level were set to 0.005 IU/ml for
calculating geometric mean titers. The correla-
tion of this method with the Vero neutralization
assay has been confirmed recently (r ³ 0.95) (9).
Antitoxin antibody levels were classified
according to international standards as
< 0.01 IU/ml (no protection), 0.01 IU/ml to
0.1 IU/ml (basic protection) and > 0.1 IU/ml (full
protection) (10).
Analysis
Frequencies and geometric mean titers in
each municipality were weighted by the proportion
of the age group in the population. To produce
national estimates, the weighted frequencies and
geometric mean titers were averaged over the 40
municipalities (7). For the low vaccine coverage
sample, they were averaged by weighting the
population of the municipality.
Data on age, sex, marital status, country of
nationality, degree of urbanization, region, and
contact information for all participants and
nonparticipants were available. The effect of
differential probabilities of response for these
variables on both sample estimates was less than
one standard error and was therefore disregarded.
Linear regression analysis was used to study
the persistence of diphtheria antitoxin antibod-
ies after full immunization in the national
immunization program. The association between
diphtheria antibody titer (2log) and age in 2log
years was studied for persons who received the
sixth documented vaccination at 8 to 9 years of
age, without self-reported or documented
revaccination or history of military service.
Age-Specific Immunity Levels to Diphtheria
Antitoxin
In the nationwide sample, 58.1%, 30.0%, and
11.9% of persons  £ 79 years of age had full, basic,
or no diphtheria protection, respectively (Table 1).
Women had lower levels of full protection and
geometric mean titers. A greater percentage of
persons from the municipalities with low vaccine
coverage and of members of religious communi-
ties in the low vaccine coverage sample had no
protection (Table 2). When members of the
religious community were excluded from this low
Table 1. Diphtheria immunity in a nationwide sample of persons £ 79 years of age, the Netherlands
<0.01 0.01-0.1 ³ 0.1 Geometric
Sample No. IU/ml (95% CIa) IU/ml (95% CI) IU/ml (95% CI) mean titer (95% CI)
Overall 7,715 11.9 (10.7-13.1) 30.0 (28.3-31.7) 58.1 (56.2-59.9) 0.12 (0.11-0.13)
Men 3,644   9.3   (8.0-10.6) 28.1 (25.9-30.2) 62.6 (60.1-65.2) 0.14 (0.13-0.16)
Women 4,071 14.4 (12.6-16.2) 31.6 (29.7-33.6) 54.0 (51.9-56.0) 0.10 (0.09-0.11)
aCI, confidence interval.
Table 2. Diphtheria immunity in a sample of persons  £ 79 years of age with low vaccine coverage, the Netherlands
Nationwide <0.01 <0.01 ³ 0.1 Geometric
samplea No. IU/ml (95% CIb) IU/ml (95% CI) IU/ml (95% CI) mean titer (95% CI)
OR
  Overall    233 60.9 (42.9-78.9) 12.4 (6.0-18.7) 26.7 (13.8-39.7) 0.02 (0.01-0.04)
  Men    116 69.7 (54.2-85.2) 10.4 (4.2-16.6) 19.9   (8.2-31.5) 0.01 (0.01-0.03)
  Women    117 52.3 (27.7-76.8) 15.0 (6.9-23.2) 32.7 (15.3-50.1) 0.03 (0.01-0.06)
NMCR
  Overall 1,259 17.5 (15.5-19.4) 25.2 (21.3-29.2) 57.3 (52.2-62.4) 0.10 (0.09-0.12)
 Men    590 11.5   (8.2-14.8) 25.5 (20.5-30.6) 63.0 (55.4-70.5) 0.14 (0.13-0.16)
  Women    669 21.7 (18.0-25.4) 25.0 (21.2-28.9) 53.3 (48.6-58.0) 0.08 (0.07-0.10)
TLVC
  Overall 1,492 24.3 (20.5-28.0) 23.6 (20.1-27.1) 52.1 (48.2-56.0) 0.08 (0.07-0.09)
  Men    706 20.6 (16.6-24.7) 23.4 (18.9-27.8) 56.0 (50.3-61.7) 0.10 (0.08-0.12)
  Women    786 26.7 (21.1-32.4) 23.3 (19.9-26.7) 50.0 (45.3-54.7) 0.07 (0.06-0.09)
aOR, orthodox reformed; NMCR, Not member of religious communities; TLVC, total low vaccine coverage.
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vaccine coverage sample, the percentages of full,
basic, and no protection were 57.3%, 25.2%, and
17.5%, respectively (Table 2).
For the ages of 1, 4, and 8 to 9 years, the
geometric mean titer and percentages of persons
with full protection increased (Table 3). The
Table 3. Age-specific prevalence of diphtheria immunity and geometric mean titers for children  £ 14 years of age and
for men and women  £ 79 years of age in a nationwide sample, the Netherlands
Age Geometric
group   <0.01 0.01-0.1 ³ 0.1 mean
(yrs)  No. IU/ml (95% CIa) IU/ml (95% CI) IU/ml (95% CI) titer  (95% CI)
<1 187   3.7     (1.1-6.4) 25.5 (18.6-32.4) 70.7 (63.4-78.1) 0.19 (0.15-0.24)
1 185   1.2     (0.0-3.0)   9.9   (5.4-14.3) 88.9 (84.3-93.5) 0.57 (0.45-0.72)
2 156   1.9     (0.1-3.7) 34.9 (24.2-45.5) 63.3 (52.9-73.6) 0.15 (0.12-0.19)
3 215   1.7     (0.1-3.3) 35.5 (27.7-43.3) 62.8 (54.7-70.9) 0.16 (0.12-0.22)
4 153   0.6     (0.0-1.7)   8.7   (3.7-13.7) 90.7 (85.7-95.7) 0.81 (0.60-1.10)
5 102   1.4     (0.0-3.3)   6.3   (1.9-10.7) 92.3 (87.7-97.0) 0.43 (0.35-0.52)
6 121   0.9     (0.0-2.6) 20.0 (11.7-28.3) 79.1 (70.9-87.4) 0.26 (0.21-0.34)
7 101   2.3     (0.0-5.4) 31.8 (20.3-43.3) 65.9 (54.7-77.2) 0.16 (0.13-0.20)
8 127   0.7     (0.0-2.0) 23.6 (14.9-32.3) 75.8 (66.9-84.6) 0.28 (0.20-0.38)
9   97   0.0     (0.0-0.0) 11.8   (3.2-20.4) 88.2 (79.6-96.8) 0.71 (0.51-0.99)
10 113   0.7     (0.0-2.1)   6.7   (1.9-11.5) 92.6 (87.7-97.5) 0.54 (0.42-0.69)
11 111   0.7     (0.0-1.9)   8.3   (3.5-13.2) 91.0 (85.8-96.2) 0.36 (0.30-0.44)
12 122   0.6     (0.0-1.9) 17.0   (9.2-24.8) 82.4 (74.2-90.5) 0.28 (0.22-0.35)
13 126   0.0     (0.0-0.0) 27.3 (18.0-36.7) 72.7 (63.3-82.0) 0.23 (0.18-0.29)
14 102   0.4     (0.0-1.1) 26.7 (14.0-39.3) 72.9 (60.3-85.6) 0.22 (0.15-0.31)
Men
<1 104   3.5   (0.04-7.0) 25.2 (15.8-34.6) 71.3 (61.4-81.2) 0.18 (0.13-0.24)
1-4 376   1.8     (0.5-3.1) 22.9 (17.0-28.8) 75.3 (69.1-81.5) 0.31 (0.25-0.38)
5-9 296   0.6     (0.0-1.4) 16.9 (12.4-21.4) 82.5 (77.9-87.1) 0.34 (0.28-0.40)
10-14 280   0.6     (0.0-1.7) 16.5 (11.7-21.3) 83.0 (78.0-88.0) 0.32 (0.27-0.38)
15-19 209   1.0     (0.0-2.4) 25.8 (19.7-31.9) 73.1 (67.1-79.1) 0.19 (0.16-0.23)
20-24 139   4.0     (0.4-7.6) 25.5 (17.8-33.2) 70.5 (62.0-79.0) 0.15 (0.12-0.19)
25-29 150   2.9     (0.0-6.2) 30.6 (21.7-39.5) 66.5 (56.9-76.1) 0.18 (0.14-0.24)
30-34 188   7.0   (1.6-12.4) 31.5 (23.0-40.0) 61.5 (52.1-70.9) 0.14 (0.10-0.19)
35-39 220   5.1     (1.3-8.9) 27.4 (20.7-34.1) 67.5 (60.8-74.2) 0.18 (0.14-0.23)
40-44 230   3.8     (1.1-6.5) 16.3 (11.0-21.6) 79.9 (73.9-85.9) 0.25 (0.20-0.31)
45-49 208 13.7   (7.8-19.6) 26.6 (21.4-31.8) 59.7 (51.8-67.6) 0.13 (0.09-0.18)
50-54 228 15.0 (10.4-19.6) 31.1 (24.7-37.5) 53.9 (46.5-61.3) 0.10 (0.08-0.13)
55-59 251   8.8   (4.0-13.6) 38.8 (32.1-45.5) 52.4 (46.0-58.8) 0.10 (0.08-0.12)
60-64 216 10.3   (6.2-14.4) 52.3 (43.8-60.8) 37.4 (29.9-44.9) 0.07 (0.06-0.09)
65-69 200 26.5 (19.6-33.4) 39.4 (30.4-48.4) 34.1 (26.2-42.0) 0.05 (0.04-0.06)
70-74 193 46.2 (36.9-55.5) 26.6 (19.2-34.0) 27.1 (19.2-35.2) 0.03 (0.02-0.04)
75-79 156 45.0 (35.8-54.2) 26.2 (17.8-34.6) 28.8 (20.8-36.8) 0.03 (0.02-0.04)
Women
<1   83   4.2     (0.0-8.9) 26.6 (13.7-39.5) 69.3 (56.7-81.9) 0.19 (0.13-0.27)
1-4 333   2.2     (0.5-3.9) 22.2 (16.7-27.7) 75.6 (70.0-81.2) 0.30 (0.25-0.37)
5-9 252   1.8     (0.0-3.7) 23.8 (16.2-31.4) 74.5 (68.2-80.8) 0.29 (0.24-0.36)
10-14 294   0.3     (0.0-0.8) 18.6 (12.9-24.3) 81.1 (75.4-86.8) 0.29 (0.24-0.33)
15-19 243   0.7     (0.0-1.7) 28.2 (21.9-34.5) 71.1 (64.8-77.4) 0.17 (0.15-0.20)
20-24 199   2.8     (0.4-5.2) 31.3 (23.6-39.0) 65.9 (58.3-73.5) 0.14 (0.12-0.18)
25-29 226   5.0     (1.5-8.5) 27.1 (20.3-33.9) 67.9 (60.5-75.3) 0.14 (0.11-0.18)
30-34 244 10.0   (5.7-14.3) 36.9 (30.5-43.3) 53.0 (47.3-58.7) 0.11 (0.09-0.13)
35-39 282   5.6     (2.5-8.7) 37.0 (29.6-44.4) 57.4 (50.6-64.2) 0.13 (0.11-0.15)
40-44 247   8.7   (4.8-12.6) 24.4 (18.5-30.3) 66.9 (60.9-72.9) 0.16 (0.12-0.20)
45-49 261 22.0 (15.8-28.2) 37.6 (30.6-44.6) 40.3 (32.3-48.3) 0.06 (0.04-0.08)
50-54 264 28.2 (20.2-36.2) 41.7 (34.5-48.9) 30.1 (23.0-37.2) 0.04 (0.03-0.05)
55-59 250 22.3 (16.3-28.3) 49.7 (43.6-55.8) 28.0 (22.3-33.7) 0.04 (0.03-0.05)
60-64 237 29.2 (22.9-35.5) 45.9 (39.7-52.1) 24.8 (19.0-30.6) 0.03 (0.02-0.04)
65-69 263 38.0 (30.6-45.4) 34.3 (29.0-39.6) 27.7 (21.3-34.1) 0.03 (0.02-0.05)
70-74 218 58.2 (50.8-65.6) 25.0 (18.9-31.1) 16.8 (11.0-22.6) 0.02 (0.01-0.02)
75-79 175 52.7 (43.8-61.6) 26.6 (19.4-33.8) 20.7 (12.7-28.7) 0.02 (0.01-0.03)
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percentage with full protection decreased after
the age of 10 to 14 years, but increased for the 35-
to 44-year age group (Figure 1). After the age of
40 to 44 years, the percentage with full protection
and the geometric mean titer decreased. Although
the geometric mean titers differed statistically
significantly by gender only after the age of 30
years, they were slightly lower for females 5 to 9
years of age and older (Table 3).
Both for orthodox reformed persons less than
50 years and for those at least 50 years of age, the
proportion with no protection was higher than
for persons in the nationwide sample (Table 4).
Men and women ages 20 to 49 years without
a military service history had similar propor-
tions of full, basic, and no protection, while the
proportion with full protection was higher for
men with a military service history (Table 5).
Persistence of Diphtheria Antitoxin Levels
The geometric mean titer decreased with age
(or time since last vaccination) for persons who
had received their sixth and last vaccination at
8 to 9 years of age (n = 961) from 0.30 IU/ml for 10
to 14 years to 0.09 IU/ml for 30 to 34 years
(Table 6, Figure 2). According to linear
regression analysis, the decrease corresponds to
a decrease of -1.27 2log IU/ml with each 2log
increase in years. The percentage with full
protection decreased from 82.5% to 41.7%, and
the percentage with no protection increased from
0% to 4.3% for persons 10 to 14 years of age and
30 to 34 years of age, respectively (Table 6).
The geometric mean titer for persons 20 to 34
years of age with documented revaccination
(n = 37) was 0.29 IU/ml. Percentages of full
(81.0%), basic (19.0%), and no protection (0.0%)
were similar to recently vaccinated 10- to
14-year-olds, without further documented or
reported revaccination (Table 6).
Conclusions
Our population-based study showed that
58% of the Dutch population had full, 30% basic,
and 12% no protection against diphtheria. These
estimates and the geometric mean titer (0.12 IU/
ml) are in between findings for other European
countries (4,11-20). The Dutch immunization
program appeared to induce long-term protec-
tion. However, approximately one third of adults
age 50 to 79 years, who were born before the
introduction of the immunization program, and
approximately two-thirds of orthodox reformed
persons had no protective diphtheria antibodies.
Figure 1. Age-specific diphtheria immunity in a
nationwide sample (n = 7715), the Netherlands.
Table 4. Diphtheria immunity in a nationwide sample and in orthodox reformed persons in municipalities with low
vaccine coverage, the Netherlands.
  Geometric
Samplea <0.01 0.01-0.1 ³0.1 mean
(yrs) No. IU/ml (95% CIb) IU/ml (95% CI) IU/ml (95% CI) titer (95% CI)
NW
0-49 5,064   5.3     (4.4-6.2) 27.3 (25.3-29.4) 67.4 (65.2-69.5) 0.17     (0.16-0.19)
50 -79 2,651 29.2 (26.4-31.9) 37.4 (35.3-39.5) 33.4 (31.3-35.6) 0.04     (0.04-0.05)
ORLVC
0-49   170 60.8 (40.2-81.4)   7.4 (2.3-12.6) 31.8 (13.8-49.7) 0.02     (0.01-0.05)
50 -79     63 59.3 (30.1-88.6) 34.6 (9.5-59.6)   6.1   (0.0-18.2) 0.01 (0.005-0.025)
aNW, nationwide; ORLVC, Orthodox reformed from low vaccine coverage sample.
bCI, confidence interval.698 Emerging Infectious Diseases Vol. 5, No. 5, SeptemberOctober 1999
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The toxin inhibition test used to measure
diphtheria antitoxin concentrations shows good
correlation with the in vitro neutralization test
in Vero cells, but is faster, simpler, and combines
the measurement of diphtheria and tetanus
antitoxin antibodies (8,9).
Although the participation rates in the
nationwide sample and low vaccine coverage
sample were 55% and 52.5%, respectively, our
population-based estimates of diphtheria immu-
nity were considered representative, because
they do not seem to be affected by
nonparticipation. Our participants included a
large percentage of persons with diphtheria
protection who were born after the vaccination
was introduced in 1952 and after the virtual
disappearance of diphtheria in 1960. High levels
of immunity in this group reflect the success of
the national vaccination program.
Table 5. Diphtheria immunity in a nationwide sample among persons 20 to 49 years of age, according to sex and
military service, the Netherlands
Geometric
<0.01 0.01-0.1 ³0.1 mean
Samplea No. IU/ml (95% CIb) IU/ml  (95% CI)  IU/ml (95% CI)  titer (95% CI)
M, SH    425 2.9   (1.2-4.6) 14.9 (11.1-18.7) 82.2 (78.0-86.5) 0.30 (0.25-0.36)
M, NSH    710 7.8 (5.2-10.3) 33.1 (28.0-38.1) 59.2 (54.0-64.4) 0.12 (0.10-0.14)
W, NSH 1,456 9.1 (7.0-11.2) 32.5 (29.0-36.0) 58.4 (54.5-62.3) 0.12 (0.10-0.13)
aM, men; W, women; SH, service history; NSH, no service history.
bCI, confidence interval.
Table 6. Diphtheria immunity for persons in a nationwide sample who were completely vaccinated in the national
immunization program and received the sixth diphtheria vaccination at 8 or 9 years of age, the Netherlands
   Geometric
Samplea <0.01 0.01-0.1 ³0.1 mean titer
(yrs) No. IU/ml (95% CIb)  IU/ml (95% CI)  IU/ml (95% CI) (IU/ml) (95% CI)
NRE
10-14 392 0.0      -- 17.5 (12.8-22.1) 82.5 (77.9-87.1) 0.30 (0.26-0.34)
15-19 282 0.4 (0.0-1.3) 30.1 (23.7-36.5) 69.4 (63.2-75.7) 0.17 (0.14-0.21)
20-24 155 1.2 (0.0-3.0) 29.4 (20.7-38.2) 69.4 (60.7-78.1) 0.16 (0.12-0.19)
25-29 80 1.6 (0.0-3.7) 28.3 (17.2-39.4) 70.2 (58.7-81.6) 0.14 (0.11-0.18)
30-34 52 4.3 (0.0-9.2) 54.0 (39.3-68.8) 41.7 (27.3-56.1) 0.09 (0.07-0.13)
RE
20-34 37 0.0      -- 19.0 (3.2-34.9) 81.0 (65.1-96.8) 0.29 (0.18-0.46)
aNRE, no evidence of revaccination; RE, evidence of revaccination.
bCI, confidence interval.
Figure 2. Diphtheria antitoxin titer (geometric mean
titer ± 2 standard errors) by age group and linear
regression of diphtheria antitoxin antibody titer (in
2log) with age (in  2log years) for persons who received
the sixth diphtheria vaccination at the age of 8 or 9
years (n = 961) in the nationwide sample, the
Netherlands.699 Vol. 5, No. 5, SeptemberOctober 1999 Emerging Infectious Diseases
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For persons born before the introduction of
vaccination, diphtheria immunity is largely
derived from natural infection. However,
immunity levels in persons older than 49 years in
the general population are higher than those of
orthodox reformed persons, suggesting that
immunity was partly induced by vaccinations
(e.g., for military service, travel).
The sharp increase in the percentage of
persons older than 44 years with no protective
diphtheria antitoxin levels is consistent with
findings of other studies (4,11,12,14-19). The
increase supports the phenomenon of waning
immunity after natural infection without boosting.
In our study, higher immunity levels among
men are associated with military service, as
previously reported (15,19). However, some
researchers have found similar immunity levels
for men and women, while others have reported
lower immunity for men (11,16,21). Further-
more, lower immunity for women that could not
be ascribed to vaccinations during military
service has also been reported (4,20). Women
might maintain immunity after vaccination for a
shorter time than men (14). The slightly lower
geometric mean titers for girls age 5 to 19 years
in our study are consistent with the latter
possibility. As more than 60% of orthodox reformed
persons have no protection against diphtheria,
introduction of diphtheria into this group may
constitute a danger of spreading the bacterium.
Since the Netherlands does not have a
mandatory vaccination policy, protection of
persons who refuse vaccination is problematic. For
poliomyelitis the solution seems to be eradication
of the causative agent (5). For diphtheria such a
goal has not yet been formulated by WHO. However,
even though systematic assessment has not been
performed, no signs of persistent circulation of
C. diphtheriae exist in the Netherlands.
When our data are interpreted longitudi-
nally, the log linear decrease in diphtheria
antibody level with age for completely vaccinated
persons corresponds with a continuous decline in
vaccine-induced antibodies (13,22). However,
relatively few 30- to 34-year-old persons (4.3%)
who received their last vaccination approxi-
mately 25 years ago had a diphtheria antitoxin
level of less than 0.01 IU/ml. This compares
favorably with observations in other countries
(13,21-23). Our immunization program, in which
children are vaccinated at 3, 4, 5, and 11 months
with 15 Lf diphtheria toxoid and at the ages of 4
and 9 years with 2.5 Lf, appears to induce long-
term protection against diphtheria.
In the Netherlands, booster vaccinations are
only advised for persons at increased risk for
exposure (e.g., travelers to endemic-disease
countries and those who work with injection
drug users and alcoholic patients). The need for
routine boosters to guarantee population protec-
tion  depends mainly on the proportion of
vaccinated persons necessary to confer diphthe-
ria herd immunity. This proportion is estimated
at 70% to 80%, but no antitoxin level has been
precisely defined for complete protection (10,13,24-
26).  The Dutch immunity level exceeds this
threshold (a minimum level of 0.01 IU/ml [88%]),
but is below a minimum level of 0.1 IU/ml (58%).
The absence of cases in the Netherlands
associated with the diphtheria epidemic in
Eastern Europe suggests that herd immunity is
sufficient. This herd immunity might result from
sufficient protective levels of antitoxin or
immunologic memory. Our results, like those of
others, indicate good immunologic memory after
revaccination for persons who had been previously
vaccinated (17, 27). However, the memory
response of adults after initial vaccination is
unknown. Furthermore, unknown protective
mechanisms might be involved. Only sporadic
cases and no outbreaks have occurred in other
European countries where gaps have been found
in the diphtheria antitoxin levels of adults. The
only recent epidemic in western Europe, which
occurred before the epidemic in eastern Europe,
was among alcoholics (23). Perhaps unfavorable
social conditions, like those that appear to have
contributed to the epidemics in eastern Europe,
play a role in the spread of diphtheria.
In conclusion, a substantial percentage of
adults born before the introduction of the
immunization program has low diphtheria
antitoxin levels. Although herd immunity seems
sufficient, long-term population protection cannot
be assured. Possibly vaccination might fill the gaps
of diphtheria antitoxin antibodies. Diphtheria
vaccination could be efficiently combined with
other vaccines (e.g., tetanus, influenza) as part of
an adult immunization program.
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